Ticker

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

InfuSystems Holdings (INFU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InfuSystem is rated a buy, leveraging a stable oncology-focused patient services segment with strong FCF yields, margin progress, and reasonable valuations. INFU offers an attractive FCF yield of 11.6%, nearly double its peer Viemed Healthcare, and trades at a reasonable forward EV/EBITDA multiple below 6.5x. Management's future financial outlook is supported by reduced Capex, ERP-driven efficiencies, and growth in…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The consensus price target hints at a 62.6% upside potential for InfuSystems Holdings (INFU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.